Pharmacological Prophylaxis Versus Pancreatic Duct Stenting Plus Pharmacological Prophylaxis for Prevention of Post-Ercp Pancreatitis in High Risk Patients: A Randomized Trial

Pharmacological Prophylaxis Versus Pancreatic Duct Stenting Plus Pharmacological Prophylaxis for Prevention of Post-Ercp Pancreatitis in High Risk Patients: A Randomized Trial Publisher Pubmed

Sotoudehmanesh R^{1, 2} ; Aliasgari A^{1, 2} ; Khatibian M^{1, 2} ; Mohamadnejad M^{1, 3} ; Merat S^{1, 2, 3} ; Sadeghi A^{1, 2} ; Keshtkar A⁴ ; Bagheri M^{1, 2} ; Delavari A^{1, 3} ; Amani M^{1, 3} ; Vahedi H^{1, 2} ; Nasserimoghaddam S^{1, 2, 3} ; Sima A^{1, 2} ; Eloubeidi MA⁵ Show All Authors

Sotoudehmanesh R^{1, 2}
Aliasgari A^{1, 2}
Khatibian M^{1, 2}
Mohamadnejad M^{1, 3}
Merat S^{1, 2, 3}
Sadeghi A^{1, 2}
Keshtkar A⁴
Bagheri M^{1, 2}
Delavari A^{1, 3}
Amani M^{1, 3}
Vahedi H^{1, 2}
Nasserimoghaddam S^{1, 2, 3}
Sima A^{1, 2}
Eloubeidi MA⁵
Malekzadeh R^{1, 2, 3}

Show Affiliations

1. Liver and Pancreaticobiliary Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Shariati Hospital, Kargar Shomali Avenue, Tehran, Iran
2. Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
3. Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
4. Department of Health Science Educational Development, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
5. Anniston Digestive Health, Anniston, AB, United States

Source: Endoscopy Published:2019

Abstract

Background, Acute pancreatitis is a serious complication of endoscopic retrograde cholangiopancreatography (ERCP). The aim of this noninferiority study was to evaluate the effectiveness of pancreatic duct (PD) stenting plus pharmacological prophylaxis vs. pharmacological prophylaxis alone in the prevention of post-ERCP pancreatitis (PEP) in high risk patients. Methods, In this randomized, controlled, double-blind, noninferiority trial, patients at high risk of developing PEP were randomly allocated to pharmacological prophylaxis (rectal indomethacin, sublingual isosorbide dinitrate, and intravenous hydration with Ringer's lactate) plus PD stenting (group A) or pharmacological prophylaxis alone (group B). The rate and severity of PEP, serum amylase levels, and length of hospital stay after ERCP were assessed. Results, During 21 months, a total of 414 patients (mean age 55.5 ± 17.0 years; 60.2 % female) were enrolled (207 in each group). PEP occurred in 59 patients (14.3 %, 95 % confidence interval [CI] 11.1 % - 17.9 %: 26 patients [12.6 %, 95 %CI 8.6 % - 17.6 %] in group A and 33 [15.9 %, 95 %CI 11.4 % - 21.4 %] in group B). There was no significant difference between the two groups in PEP severity (P = 0.59), amylase levels after 2 hours (P = 0.31) or 24 hours (P = 0.08), and length of hospital stay (P = 0.07). Conclusions, The study failed to demonstrate noninferiority or inferiority of pharmacological prophylaxis alone compared with PD stenting plus pharmacological prophylaxis in the prevention of PEP in high risk patients. © Georg Thieme Verlag KG Stuttgart New York.

2. The Synergistic Impact of Nsaids and Aggressive Hydration Therapy on the Rate of Post-Ercp Pancreatitis in High -Risk and Low -Risk Patients, Gastroenterology and Hepatology from Bed to Bench (2020)

Style	Citing Format
MLA	Sotoudehmanesh R, et al.. "Pharmacological Prophylaxis Versus Pancreatic Duct Stenting Plus Pharmacological Prophylaxis for Prevention of Post-Ercp Pancreatitis in High Risk Patients: A Randomized Trial." Endoscopy, vol. 51, no. 10, 2019, pp. 915-921.
APA	Sotoudehmanesh R, Aliasgari A, Khatibian M, Mohamadnejad M, Merat S, Sadeghi A, Keshtkar A, Bagheri M, Delavari A, Amani M, Vahedi H, Nasserimoghaddam S, Sima A, Eloubeidi MA, Malekzadeh R (2019). Pharmacological Prophylaxis Versus Pancreatic Duct Stenting Plus Pharmacological Prophylaxis for Prevention of Post-Ercp Pancreatitis in High Risk Patients: A Randomized Trial. Endoscopy, 51(10), 915-921.
Chicago	Sotoudehmanesh R, Aliasgari A, Khatibian M, Mohamadnejad M, Merat S, Sadeghi A, Keshtkar A, et al.. "Pharmacological Prophylaxis Versus Pancreatic Duct Stenting Plus Pharmacological Prophylaxis for Prevention of Post-Ercp Pancreatitis in High Risk Patients: A Randomized Trial." Endoscopy 51, no. 10 (2019): 915-921.
Harvard	Sotoudehmanesh R et al. (2019) 'Pharmacological Prophylaxis Versus Pancreatic Duct Stenting Plus Pharmacological Prophylaxis for Prevention of Post-Ercp Pancreatitis in High Risk Patients: A Randomized Trial', Endoscopy, 51(10), pp. 915-921.
Vancouver	Sotoudehmanesh R, Aliasgari A, Khatibian M, Mohamadnejad M, Merat S, Sadeghi A, et al.. Pharmacological Prophylaxis Versus Pancreatic Duct Stenting Plus Pharmacological Prophylaxis for Prevention of Post-Ercp Pancreatitis in High Risk Patients: A Randomized Trial. Endoscopy. 2019;51(10):915-921.
BibTex	@article{ author = {Sotoudehmanesh R and Aliasgari A and Khatibian M and Mohamadnejad M and Merat S and Sadeghi A and Keshtkar A and Bagheri M and Delavari A and Amani M and Vahedi H and Nasserimoghaddam S and Sima A and Eloubeidi MA and Malekzadeh R}, title = {Pharmacological Prophylaxis Versus Pancreatic Duct Stenting Plus Pharmacological Prophylaxis for Prevention of Post-Ercp Pancreatitis in High Risk Patients: A Randomized Trial}, journal = {Endoscopy}, volume = {51}, number = {10}, pages = {915-921}, year = {2019} }
RIS	TY - JOUR AU - Sotoudehmanesh R AU - Aliasgari A AU - Khatibian M AU - Mohamadnejad M AU - Merat S AU - Sadeghi A AU - Keshtkar A AU - Bagheri M AU - Delavari A AU - Amani M AU - Vahedi H AU - Nasserimoghaddam S AU - Sima A AU - Eloubeidi MA AU - Malekzadeh R TI - Pharmacological Prophylaxis Versus Pancreatic Duct Stenting Plus Pharmacological Prophylaxis for Prevention of Post-Ercp Pancreatitis in High Risk Patients: A Randomized Trial JO - Endoscopy VL - 51 IS - 10 SP - 915 EP - 921 PY - 2019 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract